-
Mar 08, 2024
-
Mar 08, 2024
-
ACTG PRESENTS STUDY AT CROI ELUCIDATING MECHANISM OF CMV ON AGING-RELATED PATHWAYS IN HIV
Mar 08, 2024
-
The first study of a broadly neutralizing antibody called SAR441236 in humans, will determine if an infusion is safe and…
Closed to accrual
HIV Treatment
Most participants will be followed on study for 24 weeks after their infusion. Participants who receive multiple infusions will be followed for a total of 72 weeks.
-
This four-step study compares Long-Acting (LA) Injectable Antiretroviral Therapy (ART) to standard of care (SOC) oral ART in previously non-adherent…
Closed to accrual
HIV Treatment
Steps 1-3 combined are a total of 128 weeks. Step 4 lasts 52 weeks.
-
Designed to develop a standard operating procedure to establish a storage bank for specimens for future HIV DNA analyses. Informed…
Open and enrolling
Hepatitis, HIV comorbidities and complications, HIV Cure, HIV Treatment, Tuberculosis
-
A5243: Non-US Genomic Sampling
Collecting blood and saliva samples from former and current ACTG study participants for future HIV-related genetic testing. This is a…
Closed to accrual
Hepatitis, HIV comorbidities and complications, HIV Cure, HIV Treatment, Tuberculosis
-
This study is for people with HIV who have an undetectable viral load. The study will evaluate the safety and…
Closed to accrual
HIV Treatment
Participants will be on study for about 101 weeks.
-
This is a study for people who have HIV and qualify to switch to or receive Dolutegravir containing antiretroviral therapy…
Closed to accrual
HIV Treatment
Each participant will be followed for 36 months.
